Chemolab Therapeutics and Scipher Medicine announced a planned merger and rebrand into Scipher Medicine Corporation, with Scipher CEO Reginald Seeto becoming CEO of the combined entity. The companies said the new organization will initially focus on advancing nebokitug, an anti-CCL24 monoclonal antibody, toward a Phase 2 rheumatoid arthritis trial. Scipher plans to use its PrismRA blood-based assay to guide patient enrollment, aiming to test nebokitug in a precision-medicine framework. The merger also includes investor financing commitments positioned to carry operations through the second half of 2028. The transaction underscores how biotech groups are consolidating around biomarker-driven immunology programs to reduce execution risk and accelerate trial readiness.